Prospective Affirmative Therapeutics of Cannabidiol Oil Mitigates Doxorubicin-Induced Abnormalities in Kidney Function, Inflammation, and Renal Tissue Changes.

Abstract

Abstract Nephropathy is the decline in kidney function. A promising treatment for a wide range of illnesses is the use of natural materials as natural chemical compounds. The inquiry was conducted to investigate CBD's potential for renal syndrome protection. The five equal groups of fifty male Sprague-Dawley rats weighing 150 ± 25g each were shaped, Group I received distilled water administered orally, while Group II got an intraperitoneal injection of doxorubicin (18 mg/kg bwt). Group III received CBD (26mg/kg bwt) orally, while Group IV received 1 ml of CBD (26 mg/kg bwt) and Group V received Trimetazidine (10 mg/kg bwt), in addition to a single intraperitoneal dose of Doxorubicin (18 mg/kg bwt) on the 11th day for both groups (IV, V). The administration of CBD (26 mg/kg bwt) led to a noticeable improvement in oxidative stress parameters (SOD and GSH) in rats by significantly lowering enzyme activity (ALT and AST), as well as serum Creatinine and urea, (IL 6), and MDA besides the anti-inflammatory accuracy of CBD linked to significant lowering to IL6 DNA frequency concentration in line with histopathology results. As a result of its anti-inflammatory and antioxidant capabilities, cannabidiol may have protective qualities as CBD medication could be linked to controlling renal problems.